Pancreatic cancer: A review of emerging therapies

Drugs

Volumn 59, Issue 5, 2000, Pages 1071-1089

  Rosenberg, Lawrence ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTIESTROGEN; CHLORAMBUCIL; CYTARABINE; DIAZIQUONE; DRUG METABOLITE; EDATREXATE; EPIDERMAL GROWTH FACTOR; FAZARABINE; FLUOROURACIL; GEMCITABINE; HORMONE; IPROPLATIN; MATRIX METALLOPROTEINASE INHIBITOR; MITOGUAZONE; MITOMYCIN; MOFAROTENE; MONOCLONAL ANTIBODY; OCTREOTIDE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TRIMETREXATE; TUMOR PROTEIN; UNINDEXED DRUG; VACCINE; VAPREOTIDE;

CELL CYCLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG INHIBITION; GENE THERAPY; HUMAN; MORTALITY; PANCREAS CANCER; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0034041801     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059050-00004     Document Type: Review

References (186)

1. 1. Landis S, Taylor M, Bolden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-30
2. 2. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin 1995; 45: 8-30
3. 3. Gudjonsson B. Cancer of the pancreas. Cancer 1987; 60: 2284-303
4. 4. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg 1986; 203: 77-81
5. 5. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 1998; 117:1464-84
6. 6. Kelly DM, Benjamin IS. Pancreatic carcinoma. Ann Oncol 1995; 6: 19-28
7. 7. Williamson RCN. Pancreatic cancer: the greatest oncologic challenge. BMJ 1988; 296: 445-6
8. 8. Gordis L, Gold EB. Epidemiology of pancreatic cancer. World J Surg 1984; 8: 808-21
9. 9. Douglass H. Adjuvant therapy for pancreatic cancer. World J Surg 1995; 19: 170-4
10. 10. American Cancer Society. Cancer facts and figures-1991. Atlanta (GA): American Cancer Society, 1991
11. 11. Connolly M, Dawson P, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987; 206: 366-73
12. 12. Singh S, Longmire W, Reber H. Surgical palliation for pancreatic cancer: The UCLA experience. Ann Surg 1990; 212: 132-9
13. 13. Ries LAG, Miller BA, Hankey BF, et al., editors. SEER cancer statistics review, 1973-1991: tables and graphs. NIH pub. no. 94-2789. Bethesda, MD: National Cancer Institute, 1994: 356-68
14. 14. Blackstock AW, Cox AD, Tepper JE. Treatment of pancreatic cancer: current limitations, future possibilities. Oncology 1996; 10: 301-30
15. 15. Flanders TY, Foulkes WD. Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet 1996; 33: 889-98
16. 16. Abruzzese JL. Pancreatic cancer: overview of current and future therapeutic approaches. Educational book of the American Society of Clinical Oncology, 33rd Annual Meeting, 1997: 65-70
17. 17. Rivenson A, Hoffman D, Prokopczyk B, et al. Induction of lung and exocrine pancreatic tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res 1988; 48: 6912-7
18. 18. Pour PM, Rivenson A. Induction of a mixed ductal-squamous-islet cell carcinoma in a rat treated with a tobacco-specific carcinogen. Am J Pathol 1989; 134: 627-31
19. 19. Hoffman D, Rivenson A, Chung FL, et al. Nicotine-derived N-nitrosamines (TSNA) and their relevance in tobacco carcinogencsis. Crit Rev Toxicol 1991; 21: 305-11
20. 20. Ogawa T, Makino T, Mizumoto K, et al. Promoting effect of truncal vagotomy on pancreatic carcinogenesis initiated with N-nitrosobis-(2-oxopropyl) amine in Syrian golden hamsters. Carcinogenesis 1991; 12: 1227-30
21. 21. Corra S, Kazakoff K, Lawson TA, et al. Cholecystokinin inhibits DNA alkylation induced by N-nitrosobis (2-oxopropyl) amine (BOP) in hamster pancreas. Cancer Lett 1992; 62: 251-6
22. 22. Hoffman D, Rivenson A, Abbi R, et al. A study of tobacco carcinogenesis: Effect of the fat content of the diet on the carcinogenic activity of 4 (methylnitros-amino)-1-(3-pyridyl)-1-butanone in F344 rats. Cancer Res 1993; 53: 2758-61
23. 23. Rosenberg L, Brown RA, Duguid WP. Development of experimental cancer in the head of the pancreas by surgical induction of tissue injury. Am J Surg 1984; 147: 146-51
24. 24. Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994; 86: 1510-6
25. 25. La Vecchia C, Boyle P, Francesschi S, et al. Smoking and cancer with emphasis on Europe. Eur J Cancer 1991; 27: 94-104
26. 26. Yeo C, Cameron J, Lillemoe K, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. Ann Surg 1995; 221: 721-33
27. 27. Rothenberg ML. New developments in chemotherapy for patients with advanced pancreatic cancer. Oncology 1996; 10: 18-22
28. 28. Rothenberg ML, Abbruzzese JL, Moore M, et al. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer 1996; 78 (3 Suppl.): 627-32
29. 29. Andersen JR, Friss-Mollek A, Hancke S, et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic adenocarcinoma. Scand J Gastroenterol 1981; 16: 973
30. 30. Frey C, Twomey P, Keehn R, et al. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981; 47: 27-32
31. 31. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ 1980; 281: 1589-91
32. 32. Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic cancer: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12
33. 33. Kelsen D. The use of chemotherapy in the treatment of advanced gastric and pancreatic cancer. Semin Oncol 1994; 21: 58-66
34. 34. Bukowski RM. Role of chemotherapy in patients with adenocarcinoma of the pancreas. Adv Oncol 1995; 11: 25
35. 35. Carter SK. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 3: 193
36. 36. Hubbard KP, Pazdur R. Ajani JA, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol 1992; 15: 524-7
37. 37. Carlson RW, Doroshow JH, Odujinrin OO, et al. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas: a phase II study of the Northern California Oncology Group. Invest New Drugs 1990; 8: 387-9
38. 38. Casper ES, Schwartz GK, Johnson B, et al. Phase II trial of edatrexate in patients with advanced pancreatic cancer. Invest New Drugs 1992; 10: 313-6
39. 39. Casper ES, Schwartz GK, Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992; 10: 205-9
40. 40. Bukowski RM, Fleming TR, MacDonald JS, et al. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: an Oncology Group study. Cancer 1993; 71: 322-5
41. 41. Linke K, Pazdur R, Abbruzzese J, et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 1991; 9: 353-6
42. 42. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417-22
43. 43. Heinemann V, Hertel LW, Grindley GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluoro-2′-deoxycytidine and 1-β-D arabinofuranosylcytosine. Cancer 1988; 48: 4024-31
44. 44. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8
45. 45. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34
46. 46. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13
47. 47. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 347-53
48. 48. Gelber RD. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol 1996; 7: 335-7
49. 49. Lawrence TS, Chang EY, Hahn T, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′deoxycytidine. Int J Radiat Oncol Biol Phys 1996; 34: 867-72
50. 50. Hoffman JP, McGinn CJ, Szarka C, et al. A phase I study of preoperative gemcitabine with radiation therapy followed by postoperative gemcitabine for patients with localized, resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1998; 17: 283
51. 51. Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1998; 17: 283
52. 52. Abbruzzese JL, Levin B, Ajani JA, et al. A phase I trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal cancer. Cancer Res 1989; 49: 4057-61
53. 53. Abbruzzese JL, Levin B, Ajani JA, et al. A pilot phase II trial of recombinant human interferon-gamma and recombinant human tumor necrosis factor in patients with gastrointestinal malignancies: results of a trial terminated by excessive toxicity. J Biol Response Modif 1992; 9: 522-7
54. 54. Andren-Sanderg A, Borg S, Dawiskiba I, et al. Estrogen receptors and estrogen binding protein in pancreatic cancer. Digestion 1982; 25: 12
55. 55. Berz C, Hollander C, Miller B. Endocrine responsive pancreatic carcinoma steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 1986; 46: 2276-81
56. 56. Greenway B, Iqbal MJ, Johnson PJ, et al. Oestrogen receptor proteins in malignant and fetal pancreas. BMJ 1981; 283: 751-3
57. 57. Satake K, Yoshimoto T, Mukai R, et al. Estrogen receptors in 7,12-dimethylbenz (a) anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. Clin Oncol 1982; 8: 49-54
58. 58. Sandberg AA, Rosenthal HE. Steroid receptors in exocrine glands: the pancreas and prostate. J Steroid Biochem 1979; 11: 293-9
59. 59. Pousette A, Carlstrom K, Skoldefors H, et al. Purification and partial characterization of a 17β-estradiol-binding macromolecule in the human pancreas. Cancer Res 1982; 42: 633-7
60. 60. Theve NO, Pousette A, Carlstrom K. Adenocarcinoma of the pancreas - a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9: 193-7
61. 61. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer 1993; 71: 2200-3
62. 62. Lewin MJM. The somatostatin receptors in the GI tract. Annu Rev Physiol 1992; 54: 455-69
63. 63. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-8
64. 64. Arnold R, Benning R, Neuhaus R, et al. Gastroenteropancreatic endocrine tumors: effect of sandostatin on tumor growth. Digestion 1993; 54 Suppl. 1: 72-5
65. 65. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6977-85
66. 66. Johnson LR. Effects of gastrointestinal hormones on pancreatic growth. Cancer 1981; 47: 1640-5
67. 67. Comaru-Schally M, Schally AV. LH-RH agonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer. In: Lunefield B, Vickery B, editors. International symposium on Gn-RH analogues in cancer and human reproduction. Boston: Kluwer Academic Publishers, 1990: 203-10
68. 68. Konturek SJ, Bilski J, Jaworek J, et al. Comparison of somatostatin and its highly potent hexa-and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc Soc Exp Biol Med 1988; 187: 241-9
69. 69. Stoscheck CM, King Jr LE. Role of epidermal growth factor in carcinogenesis. Cancer Res 1986; 46: 1030-7
70. 70. Goustin AS, Leof EB, Shipley GS, et al. Growth factors and cancer. Cancer Res 1986; 46: 1015-29
71. 71. Korc M, Magnum BE. Recycling of epidermal growth factor in a human pancreatic carcinoma cell line. Proc Natl Acad Sci U S A 1985; 82: 6172-5
72. 72. Lamberts SWJ, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281-7
73. 73. Pollak M, Constantino J, Polychronakos C, et al. Effect of tamoxifen on serum insulinlike growth factor I levels in stage 1 breast cancer patients. J Natl Cancer Inst 1990; 82: 1693-7
74. 74. Pollak M, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Res 1989; 9: 889-91
75. 75. Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 1994; 203 (1): 253-9
76. 76. Poston GJ, Townsend Jr CM, Rajaraman S, et al. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 1990; 5: 151-7
77. 77. Klijn JGM, Hoff AM, Th AS, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumors with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990; 62: 627-30
78. 78. Yamada Y, Post SR, Wang K, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992; 89: 251-5
79. 79. Yamada Y, Reisine T, Law S, et al. Somatosustin receptors, an expanding gene family cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 1992; 6: 2136-42
80. 80. Xu Y, Song J, Bruno JF, et al. Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochem Biophys Res Commun 1993; 193: 648-52
81. 81. Yamada Y, Kagimoto S, Kubota A, et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSThS) human somatostatin receptor subtype. Biochem Biophys Res Commun 1993; 195: 844-52
82. 82. Bell GI, Reisine T. Molecular biology of somatostatin receptors. Trends Neurosci 1993; 16: 34-8
83. 83. Hoyar D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-8
84. 84. Buscail L, Delesque N, Esteve J-P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A 1994: 91: 2315-9
85. 85. Buscail L, Esteve J-P, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR@ and SSSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995; 92: 1580-4
86. 86. Raynor K, Murphy WA, Coy DH, et al. Cloned somatostatin receptors: identification of subtype selective peptides and demonstration of high affinity linear peptides. Mol Pharmacol 1993; 43: 838-44
87. 87. O'Carroll A-M, Raynor K, Lolait SJ, et al. Characterization of cloned human somatostatin receptor SSTR5. Mol Pharmacol 1994; 46: 291-8
88. 88. Patel YC, Srikant CB. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994; 135: 2814-7
89. 89. Upp JR, Olson D, Polson FJ, et al. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg 1988; 155: 29-35
90. 90. Liebow C, Reilly C, Serrano M, et al. Somatostatin analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A 1989; 86; 2003-7
91. 91. Fisher WE, Boros LG, O'Dorisio MS, et al. Somatostatin receptor status of pancreatic adenocarcinoma predicts response to somatostatin therapy in vitro and in vivo. Surg Forum 1995; 46: 137-40
92. 92. Fisher WE, Muscarella P, O'Dorisio TP, et al. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery 1996; 120: 234-40
93. 93. Vidal C, Rauly I, Zeggari M, et al. Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cells. Mol Pharmacol 1994; 45: 97-104
94. 94. Lamberts SWJ, von Koetsveld P, Hofland LJ. The interrelationship between the antimitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin. Int J Cancer 1991; 48: 938-41
95. 95. Weckbecker G, Raulf F, Tolcsvai L, et al. Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 1996; 57 Suppl. 1: 22-8
96. 96. Radulovic S, Nagy A, Szoke B, et al. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic xenografts in nude mice. Cancer Lett 1992; 62: 263-71
97. 97. Vennin PH, Peyret JP, Bonneterre J. Effect of the long-acting somatostatin analogue SMS 201-995 in advanced breast cancer. Anticancer Res 1989; 9: 153-6
98. 98. Guliana JM, Guillausseau PJ, Caron J, et al. Effects of short-term subcutaneous administration of SMS 201-995 on calcitonin plasma levels in patients suffering from medullary thyroid carcinoma. Horm Metab Res 1989; 21: 584-6
99. 99. Kraenzlin ME, Ch'ng JC, Wood SM, et al. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185-7
100. 100. Parmar H, Bogden A, Mollard M, et al. Somatostatin and somatostatin analogues in oncology. Cancer Treat Rev 1989; 16: 95-115
101. 101. Morisset J, Genik P, Lord A, et al. Effects of chronic administration of somatostatin on rat exocrine pancreas. Regul Pept 1982; 4: 49-58
102. 102. Fekete M, Zalatnai A, Comura-Schally AM, et al. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 1989; 4: 521-8
103. 103. Davies NM, Kapur P, Gillespie J, et al. Inhibitory effect of somatostatin analog RC-160 on EGF-and transforming growth factor alpha (TGF-α)-stimulated pancreatic cancer growth in vivo. Br J Cancer 1991; 64 Suppl. 15: 4
104. 104. Schally AV, Srkalovic G, Szende B, et al. Anti-tumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies. J Steroid Biochem Mol Biol 1990; 37: 1061-7
105. 105. Szende B, Srkalovic G, Schally AV, et al. Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer 1990; 65: 2279-90
106. 106. Paz-Bouza JR, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogues of somatostatin and luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A 1987; 84: 1112-6
107. 107. Poston GJ, Gillespie J, Guillou PJ. Biology of pancreatic cancer. Gut 1991; 32: 800-12
108. 108. Szende B, Zalatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancer of hamsters after administration of analogs of luteinizing hormone releasing hormone and somatostatin. Proc Natl Acad Sci U S A 1989; 86: 1643-7
109. 109. Klijn JGM, Setyono-Han B, Bakker GH, et al. Effects of somatostatin analog (sandostatin) treatment in experimental and human cancer. In: Klijn JGM, Paridaens R, Foekens JA, editors. Hormonal manipulation of cancer: peptides, growth factors and new (anti) steroidal agents. EORTC monograph series, Vol. 19. New York (NY): Raven Press, 1987: 459-68
110. 110. Friess H, Buchler M, Beglinger Ch, et al. Low dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8: 540-5
111. 111. Frieß H, Buchler M, Ebert M, et al. Treatment of advanced pancreatic cancer with high dose octreotide. Int J Pancreatol 1993; 14: 290-1
112. 112. Ebert M, Frieß H, Beger H, et al. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994; 55 Suppl. 1: 48-51
113. 113. Scambia G, Benedetti BP, Baiochhi G, et al. Antiproliferative effects of somatostatin analog SMS 201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol 1988; 144: 106-8
114. 114. Cascinu S, Del Ferro E, Catalano G. A randomized trial of octreotide vs best supportive care only in advanced cancer patients refractory to chemotherapy. Br J Cancer 1995; 71: 97-101
115. 115. Canobbio L, Boccardo F, Cannata D, et al. Treatment of advanced pancreatic cancer with the somatosiatin analogue BIM 23014. Cancer 1992; 69: 648-50
116. 116. Huguier M, Samama G, Testart J., et al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). Am J Surg 1992; 164: 348-53
117. 117. Weckbecker G, Tolcsvai L, Stolz B, et al. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 54: 6334-7
118. 118. Rosenberg L, Barkun AN, Denis MH, et al. Low-dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75: 23-8
119. 119. Fazeny B, Baur M, Prohaska M, et al. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer: results of a pilot study and review of the literature. J Cancer Res Clin Oncol 1997; 123: 45-52
120. 120. Corbishley TP, Iqbal MJ, Wilkinson ML, et al. Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 1986; 57: 1992-5
121. 121. Iqbal MJ, Greenway BA, Wilkinson WL, et al. Sex steroid enzymes, aromatase and 5α reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin Sci 1983; 65: 71-5
122. 122. Greenway BA, Duke D, Pym B, et al. The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg 1982; 69: 595-7
123. 123. Greenway BA. Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial. BMJ 1998; 316: 1935-8
124. 124. Ryan DP, Fuchs C. Chemotherapy for pancreatic cancer. Adv Oncol 1998; 14: 11-9
125. 125. Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994; 77: 175-8
126. 126. Kawa S, Nikaido T, Aoki Y, et al. Arotinoid mofarotene (R040-8757) up-regulates p21 and p27 during growth inhibition of pancreatic cancer cell lines. Int J Cancer 1997; 72: 906-11
127. 127. Joshhi US, Dergham ST, Chen YQ. et al. Inhibition of pancreatic tumour cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 1998; 16: 107-13
128. 128. Dergham ST, Dugan MC, Joshi US, et al. The clinical significance of p21WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma. Cancer 1997; 80: 372-81
129. 129. Joshi US, Dergham ST, Chen YQ, et al. Inhibition of pancreatic tumor cell growth in culture by p21WAF1 recombinant adenovirus. Pancreas 1998; 16: 107-13
130. 130. Mohammad RM, Dugan MC, Mohamed AN, et al. Establishment of human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998; 16: 19-25
131. 131. Lee JH, Federoff HJ, Schoeniger LO, et al. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro. J Gastrointest Surg 1999; 3: 127-33
132. 132. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1: 938-43
133. 133. Yazaki T, Manz HJ, Rabkins SD, et al. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995; 55: 4752-6
134. 134. Link Jr CJ, Levy LP, McCann LZ, et al. Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J Surg Oncol 1997; 64: 289-94
135. 135. Yeo C. Pancreatic cancer: 1998 update. J Am Coll Surg 1998; 187: 429-42
136. 136. Clary BM, Coveney EC, Blazer DG, et al. Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery 1996; 120: 174-81
137. 137. Simons JW, Jalfee EM, Weber C, et al. Bioactivity of human GM-CSF gene transduced autologous renal vaccines. Cancer Res 1997; 57: 1537-46
138. 138. Cheson BD, Phillips PH, Sanol M. National Cancer Institute. Clinical trials. Oncology 1997; 11: 81-90
139. 139. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998; 4: 194-203
140. 140. Friess H, Gassmann M, Buchler MW. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Int J Pancreatol 1997; 11: 43-52
141. 141. Sears HF, Steplewski Z, Herlyn D, et al. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Mod 1984; 3: 138-50
142. 142. Adams DO, Hall T, Steplewski Z, et al. Tumors undergoing regression induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibodycytolysis. Proc Natl Acad Sci U S A 1984: 81: 3506-10
143. 143. Tempero MA, Pour PM, Uchida E, et al. Monoclonal antibody CO 17-1A and leukopheresis in immunotherapy of pancreatic cancer. Hybridoma 1986; 5 Suppl. 1: 133-8
144. 144. Sindelar WF, Maher MM, Herlyn D, et al. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results. Hybridoma 1986; 5 Suppl. 1: 125-32
145. 145. Tempero MA, Sivinski CL, Steplewski Z, et al. Phase II trial of gamma interferon and monoclonal antibody 17-1A in pancreatic cancer: biological and clinical effects. J Clin Oncol 1990; 8: 2019-26
146. 146. Tempero MA, Haga Y, Sivinski C, et al. Immunotherapy with monoclonal antibody (MAB) in pancreatic adenocarcinoma. Int J Pancreatol 1991; 9: 125-34
147. 147. Weiner LM, Haney F, Padavic-Shaller K, et al. Phase 11 multi-center evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother 1993; 13: 110-6
148. 148. Bosslet K, Kern HF, Kanzy FJ, et al. A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I: Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas. Cancer Jmmunol Immunother 1986; 23: 185-91
149. 149. Kubel R, Buchler M, Baczako K, et al. Immunohistochemistry in pancreatic cancer with new monoclonal antibodies. Lang Arch Chir 1987; 371: 243-52
150. 150. Montz R, Klapdor R, Rothe B, et al. Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma. Nuklearmedizin 1986; 25: 239-44
151. 151. Kern HF, Bosslet K, Mollenhatter J, et al. Monocyte-related functions expressed in cell lines established from human pancreatic adenocarcinoma. I. Comparative analysis of endocytotic activity, lysosomal enzyme secretion, and superoxide anion production. Pancreas 1987; 2: 212-21
152. 152. Kern HF, Bosslet K, Sedlacek HH, et al. Monocyte-related functions expressed in cell lines established from human pancreatic adenocarcinoma. II. Inhibition of stimulated activity by monoclonal antibodies reacting with surface antigens on tumor cells. Pancreas 1988; 3: 2-10
153. 153. Klapdor R, Lander S, Bahlo M, et al. Radioimmunotherapy of xenografts of human pancreatic carcinomas intravenous and intratumoral application of 131I-labeled monoclonal antibodies. Nuklearmedizin 1986; 25: 235-8
154. 154. Buchler M, Kubel R, Malfertheiner P, et al. Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494. Dtsch Med Wochenschr 1988; 113: 374-80
155. 155. Buchler NI, Friess H, Malfertheiner P, et al. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990; 7: 151-7
156. 156. Buchler M, Friess H, Schultheiss KH, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494i32) in resectable pancreatic cancer. Cancer 1991; 68: 1507-12
157. 157. Buchler M, Kubel R, Klapdor R, et al. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494: results from a multicentric phase I-II trial. In: Beger HG, Buehler M, Schulz G, et al., editors. Cancer therapy. Berlin: Springer. 1989: 3241
158. 158. Friess H, Buchler M, Schulz G, et al. Therapy of pancreatic carcinoma with the monoclonal antibody BW494/32: first clinical results. Immunitat Infekt 1989; 17: 2-26
159. 159. Bosslet K, Keweloh HC, Hermentin P, et al. Percolation and binding of monoclonal antibody BW494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities. Br J Cancer 1990; 10: 37-9
160. 160. Goodman GE, Hellstrom I, Yelton D, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993: 36: 267-73
161. 161. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989; 73: 1936-41
162. 162. Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 1990: 4: 188-93
163. 163. Svensson HP, Kadow JF, Vrudhula VM, et al. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconjug Chem 1992; 3: 176-81
164. 164. Senter PD, Wallace PM, Svensson HP, et al. Activation of prodrugs by antibody-enzyme conjugates. Adv Exp Med Biol 1991; 303: 97-105
165. 165. Stalb F, Link KH, Mitchell MS. Immunomodulation of pancreatic cancer in vitro. Effect of monoclonal antibodies, GM-CSF and lymphokine-activated killer cells. Digestion 1992: 52: 124
166. 166. Butera J, Malachovsky M, Rathore R, et al. Novel approaches in development for the treatment of pancreatic cancer. Front Biosci 1998; 3: E226-9
167. 167. Nagakawa T, Konishi I, Higashino Y, et al. The spread and prognosis of carcinoma in the region of the pancreatic head. Jpn J Surg 1989; 19: 510-8
168. 168. Nagakawa T, Kavahara M, Ueno K, et al. A clinicopathologic study on neural invasion in cancer of the pancreatic bead. Cancer 1992; 69: 930-5
169. 169. Mollenhauer J, Roether I, Kern HF. Distribution of extracellular matrix proteins in pancreatic ductal adenocarcinoma and its influence on tumor cell proliferation in vitro. Pancreas 1987; 2: 14-24
170. 170. Bramhall SR. The matrix metalloproteinases and their inhibitors in pancreatic cancer. Int J Pancreatol 1997; 21: 1-12
171. 171. Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochem Biophys Acta 1989; 989: 65-84
172. 172. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980; 284: 67-8
173. 173. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51 Suppl.: 5054-9s
174. 174. Martinez-Hernandez A, Amenta PS. The basement membrane in pathology. Lab Invest 1983; 48: 650-77
175. 175. Forster SJ, Talbot IC, Clayton DG, et al. Tumour basement membrane laminin in adenocarcinoma of rectum: an immunohistochemical study of biological and clinical significance. Int J Cancer 1986; 37: 813-7
176. 176. Charpin C, Lissitzky JC, Jacquemier J, et al. Immunohistochemical detection of laminin in 98 human breast carcinomas: a light and electron microscopic study. Hum Pathol 1986; 17: 355-65
177. 177. Lee CS, Montebello J, Georgiou T, et al. Distribution of type IV collagen in pancreatic adenocarcinoma and chronic pancreatitis. Int J Exp Pathol 1994; 75: 79-83
178. 178. Wang Z-h, Manabe T, Ohshio C. et al. Immunohistochemical study of heparan sulfate proteoglycan in adenocarcinomas of the pancreas. Pancreas 1994; 9: 758-63
179. 179. Cottam DW, Rees RC. Regulation of matrix metalloproteinases: their role in tumor invasion and metastasis (review). Int J Oncol 1993; 2: 861-72
180. 180. Docherty AJ, Murphy C. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. Ann Rheum Dis 1990; 49: 469-79
181. 181. Brown T, Tangen C, Fleming T, et al. A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 1993; 12: 200
182. 182. Kaue SB. Docetaxel (taxotere) in the treatment of solid tumors other than breast and lung cancer. Semin Oncol 1995; 22(4): 30-3
183. 183. Rougier D, DeForin M, Ademis A, et al. Phase II study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1994; 13: 200
184. 184. Stehlin JS, Giovanella BC, Natelson EA, et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14: 821-31
185. 185. Zetter BR. Angiogenesis and tumor metastases. Ann Rev Med 1998; 49: 407-24
186. 186. Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent Results Cancer Res 1998; 152: 341-52